摘要
同型半胱氨酸(HCY)和硫化氢(H2S)是含硫氨基酸代谢过程中产生的重要分子。同型半胱氨酸代谢是生物功能所必需的甲基基团供应的中心。同型半胱氨酸既可以再生为蛋氨酸,也可以代谢为半胱氨酸,是谷胱甘肽合成的前体。胱硫醚-β-合成酶(CBS)和胱硫醚-γ裂解酶(CSE)在代谢半胱氨酸半胱氨酸通过代谢途径中起着至关重要的作用。这两种酶也通过脱硫反应产生H2S。H2S在生理水平上充当气体介质,具有多方面的作用。同型半胱氨酸和H2S代谢失衡有牵连的病理条件下,包括氧化应激、炎症、心血管疾病和脑功能障碍、脂肪肝缺血再灌注损伤。肝、肾、肠和胰腺等器官含有同型半胱氨酸代谢所需的所有酶。肾脏在清除同型半胱氨酸中起重要作用。高同型半胱氨酸血症,血浆Hcy水平升高的情况下,是患者最常见的临床表现与慢性肾脏疾病(CKD)或急性肾损伤(AKI),后者常因缺血再灌注。本文综述了现有文献关于(1)肾脏在调节Hcy和H2S代谢中的作用;(2)含硫氨基酸代谢过程中的缺血再灌注中断;(3)对肾功能的Hcy和H2S代谢失衡的影响。在生理和病理生理条件下更好地了解调节HCY和H2S代谢的分子机制将有助于改善肾脏疾病或其他器官损伤患者的治疗策略。
关键词: 同型半胱氨酸、硫化氢、含硫氨基酸、缺血再灌注、经硫途径、氧化应激。
Current Medicinal Chemistry
Title:Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease
Volume: 25 Issue: 3
关键词: 同型半胱氨酸、硫化氢、含硫氨基酸、缺血再灌注、经硫途径、氧化应激。
摘要: Homocysteine (Hcy) and hydrogen sulfide (H2S) are important molecules produced during the metabolism of sulfur-containing amino acids. Hcy metabolism is central to the supply of methyl groups that are essential for biological function. Hcy can be either regenerated to methionine or metabolized to cysteine, a precursor for glutathione synthesis. Cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE) play a crucial role in metabolizing Hcy to cysteine through the transsulfuration pathway. These two enzymes are also responsible for H2S generation through desulfuration reactions. H2S, at physiological levels serves as a gaseous mediator and has multifaceted effects. Metabolic imbalance of Hcy and H2S has been implicated in pathological conditions including oxidative stress, inflammation, cardiovascular and cerebral dysfunction, fatty liver disease and ischemiareperfusion injury. Organs such as liver, kidney, gut and pancreas contain all the enzymes that are required for Hcy metabolism. The kidney plays an important role in removing Hcy from the circulation. Hyperhomocysteinemia, a condition of elevated blood Hcy level, is a common clinical finding in patients with chronic kidney disease (CKD) or acute kidney injury (AKI), the latter is often caused by ischemia-reperfusion. This paper reviews exiting literatures regarding (1) the role of kidney in regulating Hcy and H2S metabolism; (2) disruption of sulfur-containing amino acid metabolism during ischemiareperfusion; (3) impact of metabolic imbalance of Hcy and H2S on kidney function. Better understanding of molecular mechanisms that regulate Hcy and H2S metabolism under physiological and pathophysiological conditions will help improve therapeutic strategies for patients with kidney disease or other organ injuries.
Export Options
About this article
Cite this article as:
Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease, Current Medicinal Chemistry 2018; 25 (3) . https://dx.doi.org/10.2174/0929867324666170509145240
DOI https://dx.doi.org/10.2174/0929867324666170509145240 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Chemistry Strategies Towards SO<sub>2</sub> Donors as Research Tools and Potential Therapeutics
Current Topics in Medicinal Chemistry Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Mitochondria: the Headquarters in Ischemia-Induced Neuronal Death
Central Nervous System Agents in Medicinal Chemistry Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis
Current Medicinal Chemistry Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Reperfusion Therapies in Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design